HomeProductsBioactive CompoundsDNA Damage & RepairATM/ATRAzd-1390
Chemical structure of CAS 2089288-03-7

Azd-1390

CAS No.2089288-03-7
MDL No.N/A
MFC27H32FN5O2
MW477.60
InChI KeyVQSZIPCGAGVRRP-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.2089288-03-7
Product NameAzd-1390

Associated Conditions

non-small cell lung carcinoma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.

The Journal of pharmacology and experimental therapeutics • Vol. 383, Issue 1 • 2022
PMID: 36137710PMC: PMC9513858DOI: 10.1124/jpet.122.001230

The brain-penetrant ATM inhibitor, AZD1390, promotes axon regeneration and functional recovery in preclinical models of spinal cord injury.

Clinical and translational medicine • Vol. 12, Issue 7 • 2022
PMID: 35818848PMC: PMC9274214DOI: 10.1002/ctm2.962

Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.

Neuro-oncology • Vol. 23, Issue 4 • 2021
PMID: 33123736PMC: PMC8041329DOI: 10.1093/neuonc/noaa238

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Science advances • Vol. 4, Issue 6 • 2018
PMID: 29938225PMC: PMC6010333DOI: 10.1126/sciadv.aat1719

Documentation

Similar Products